HealthTech
Hetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India
[ad_1]
Hyderabad (Telangana) [India], September 25: In a landmark initiative to expand affordable breast cancer treatment in India, Hetero Healthcare Limited has announced the launch of Perzea, its most cost-effective biosimilar of Pertuzumab. Developed through a semi-exclusive collaboration with Enzene Biosciences Limited, this breakthrough aims to reduce the economic barriers faced by thousands of HER2-positive breast cancer patients.
Bringing Advanced Cancer Care Within Reach
Pertuzumab, a monoclonal antibody, is globally recognised as…
[ad_2]
Source link
Continue Reading